Arylimidamides Have Potential for Chemoprophylaxis against Blood-Transmitted Chagas Disease
Chagas disease (CD) affects over 6 million people worldwide and can be transmitted iatrogenically. Crystal violet (CV) was previously used for pathogen reduction but has harmful side-effects. In the present study, three arylimidamides (AIAs) and CV were used to sterilize mice blood samples experimentally contaminated with bloodstream trypomastigotes (BT) of Trypanosoma cruzi, at non hemolytic doses. All AIAs were not toxic to mouse blood cells until the highest tested concentration (96 µM). The previous treatment of BT with the AIAs impaired the infection establishment of cardiac cell cultures. In vivo assays showed that pre-incubation of mouse blood samples with the AIAs and CV (96 µM) significantly suppressed the parasitemia peak, but only the AIA DB1831 gave ≥90% animal survival, while vehicle treated samples reached 0%. Our findings support further studies regarding the potential use of AIAs for blood bank purposes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Pathogens (Basel, Switzerland) - 12(2023), 5 vom: 12. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Timm, Bruno Lisboa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Arylimidamides |
|---|
| Anmerkungen: |
Date Revised 30.05.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/pathogens12050701 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357445988 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357445988 | ||
| 003 | DE-627 | ||
| 005 | 20231226072616.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/pathogens12050701 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1191.xml |
| 035 | |a (DE-627)NLM357445988 | ||
| 035 | |a (NLM)37242371 | ||
| 035 | |a (PII)701 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Timm, Bruno Lisboa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Arylimidamides Have Potential for Chemoprophylaxis against Blood-Transmitted Chagas Disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.05.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Chagas disease (CD) affects over 6 million people worldwide and can be transmitted iatrogenically. Crystal violet (CV) was previously used for pathogen reduction but has harmful side-effects. In the present study, three arylimidamides (AIAs) and CV were used to sterilize mice blood samples experimentally contaminated with bloodstream trypomastigotes (BT) of Trypanosoma cruzi, at non hemolytic doses. All AIAs were not toxic to mouse blood cells until the highest tested concentration (96 µM). The previous treatment of BT with the AIAs impaired the infection establishment of cardiac cell cultures. In vivo assays showed that pre-incubation of mouse blood samples with the AIAs and CV (96 µM) significantly suppressed the parasitemia peak, but only the AIA DB1831 gave ≥90% animal survival, while vehicle treated samples reached 0%. Our findings support further studies regarding the potential use of AIAs for blood bank purposes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chagas disease | |
| 650 | 4 | |a Trypanosoma cruzi | |
| 650 | 4 | |a arylimidamides | |
| 650 | 4 | |a blood bank | |
| 650 | 4 | |a chemoprophylaxis | |
| 700 | 1 | |a da Gama, Aline Nefertiti Silva |e verfasserin |4 aut | |
| 700 | 1 | |a Batista, Marcos Meuser |e verfasserin |4 aut | |
| 700 | 1 | |a Batista, Denise da Gama Jaén |e verfasserin |4 aut | |
| 700 | 1 | |a Boykin, David W |e verfasserin |4 aut | |
| 700 | 1 | |a De Koning, Harry P |e verfasserin |4 aut | |
| 700 | 1 | |a Correia Soeiro, Maria de Nazaré |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pathogens (Basel, Switzerland) |d 2011 |g 12(2023), 5 vom: 12. Mai |w (DE-627)NLM22512761X |x 2076-0817 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:5 |g day:12 |g month:05 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/pathogens12050701 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 5 |b 12 |c 05 | ||